Uploaded November 2026 | Updated November 2026, 7 hours ago
Human genetics has laid the foundation for numerous therapeutic advances, and the integration of protein quantitative trait loci (pQTL) mapping is now accelerating this progress. The SCALLOP consortium has assembled one of the largest resources of multiplex proteomics integrated with genome-wide association data, encompassing more than 65,000 individuals. This unique dataset provides unprecedented statistical power for drug target identification.
We will discuss how systematic pQTL mapping is uncovering causal roles for circulating proteins in cardiometabolic disorders, inflammatory diseases, and cancer. By leveraging approaches such as Mendelian randomization and genetic colocalization, hundreds of pQTLs have been linked to disease pathways, enabling mechanistic insights and target prioritization.
Looking ahead, we will explore next-generation directions in pQTL research, including longitudinal proteomic profiling, tissue-specific analyses, and genetic recall studies. Together, these efforts will deepen our understanding of protein-mediated disease mechanisms and advance the discovery of novel therapeutic targets.
Speakers:
Per Eriksson - Head of Data Science Customer Applications at Olink, part of Thermo Fisher Scientific
Anders Mälarstig - Affiliate Researcher at Karolinska University
Human genetics has laid the foundation for numerous therapeutic advances, and the integration of protein quantitative trait loci (pQTL) mapping is now accelerating this progress. The SCALLOP consortium has assembled one of the largest resources of multiplex proteomics integrated with genome-wide association data, encompassing more than 65,000 individuals. This unique dataset provides unprecedented statistical power for drug target identification.
We will discuss how systematic pQTL mapping is uncovering causal roles for circulating proteins in cardiometabolic disorders, inflammatory diseases, and cancer. By leveraging approaches such as Mendelian randomization and genetic colocalization, hundreds of pQTLs have been linked to disease pathways, enabling mechanistic insights and target prioritization.
Looking ahead, we will explore next-generation directions in pQTL research, including longitudinal proteomic profiling, tissue-specific analyses, and genetic recall studies. Together, these efforts will deepen our understanding of protein-mediated disease mechanisms and advance the discovery of novel therapeutic targets.
Speakers:
Per Eriksson - Head of Data Science Customer Applications at Olink, part of Thermo Fisher Scientific
Anders Mälarstig - Affiliate Researcher at Karolinska University










